Cargando…

The Effect of Zoledronic Acid on Bone Microarchitecture and Strength after Denosumab and Teriparatide Administration: DATA‐HD Study Extension

The combination of denosumab and teriparatide is an effective treatment strategy in postmenopausal osteoporosis, though skeletal gains are promptly lost when these agents are discontinued. In the DATA‐HD study, we reported that a single dose of zoledronic acid (ZOL) maintains the increases in areal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ramchand, Sabashini K., David, Natalie L., Lee, Hang, Bruce, Michael, Bouxsein, Mary L., Tsai, Joy N., Leder, Benjamin Z.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Clinical Trials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098948/ https://www.ncbi.nlm.nih.gov/pubmed/36333954 http://dx.doi.org/10.1002/jbmr.4737

Ejemplares similares

Bone Microarchitecture and Strength Changes During Teriparatide and Zoledronic Acid Treatment in a Patient with Pregnancy and Lactation-Associated Osteoporosis with Multiple Vertebral Fractures
por: Treurniet, Sanne, et al.
Publicado: (2023)

Effect of Denosumab and Teriparatide on Fracture Nonunion
por: Boutin, Regine, et al.
Publicado: (2023)

Effect of Denosumab Compared With Risedronate on Bone Strength in Patients Initiating or Continuing Glucocorticoid Treatment
por: Geusens, Piet, et al.
Publicado: (2022)

The influence of zoledronate and teriparatide on gamma delta T cells in mice
por: Yamachika, Eiki, et al.
Publicado: (2017)

Circulating Osteogenic Progenitor Cells Enhanced with Teriparatide or Denosumab Treatment
por: Giner, Mercè, et al.
Publicado: (2022)

Advances and Unmet Needs in the Therapeutics of Bone Fragility
por: Ramchand, Sabashini K., et al.
Publicado: (2018)

Cost-Effectiveness of Sequential Teriparatide/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
por: You, Ruxu, et al.
Publicado: (2022)

Zoledronic acid sequential to teriparatide may promote greater inhibition of bone resorption than zoledronic acid alone
por: Giveon, Sharon, et al.
Publicado: (2023)

Response to teriparatide in Chinese patients with established osteoporosis: osteocalcin and lumbar spine bone-mineral density changes from teriparatide Phase III study
por: Lu, Chunyan, et al.
Publicado: (2017)

Denosumab Treatment for Giant Cell Tumor of the Spine Including the Sacrum
por: Bukata, Susan V., et al.
Publicado: (2021)

Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment
por: Hirooka, Yasuaki, et al.
Publicado: (2021)

Efficacy of switching from teriparatide to zoledronic acid or denosumab on bone mineral density and biochemical markers of bone turnover in older patients with severe osteoporosis: a real-life study
por: Dito, Giorgia, et al.
Publicado: (2023)

Efficacy of zoledronate, denosumab or teriparatide in postmenopausal women with type 2 diabetes mellitus at high risk of fragility fractures: protocol of an open, blinded endpoint randomized controlled pilot trial
por: Prasad, Trupti Nagendra, et al.
Publicado: (2023)

Efficacy of the Combination of Teriparatide and Denosumab in the Treatment of Postmenopausal Osteoporosis: A Meta-Analysis
por: Sun, Yang, et al.
Publicado: (2022)

Sequential treatment with zoledronic acid followed by teriparatide or vice versa increases bone mineral density and bone strength in ovariectomized rats
por: Shimizu, T., et al.
Publicado: (2017)

Effects of teriparatide in Chinese and Caucasian women with osteoporosis: bridging study on efficacy
por: Xie, Zhongjian, et al.
Publicado: (2019)

Modeling‐Based Bone Formation in the Human Femoral Neck in Subjects Treated With Denosumab
por: Dempster, David W, et al.
Publicado: (2020)

Cost-Effectiveness of Sequential Denosumab/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
por: You, Ruxu, et al.
Publicado: (2022)

Insufficient Mitigation of Bone Loss by Zoledronic Acid after Treatment with Denosumab
por: Park, Jung-Wee
Publicado: (2021)

Local and global microarchitecture is associated with different features of bone biomechanics
por: Roux, Jean-Paul, et al.
Publicado: (2020)

Defining Zoledronate’s Duration of Action and Optimal Dosing Interval for an Effective Therapy
por: Silverman, Stuart L.
Publicado: (2010)

Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment
por: Hirooka, Yasuaki, et al.
Publicado: (2020)

OR13-06 Romosozumab After Denosumab Improves Lumbar Spine Bone Mineral Density And Microarchitecture Greater Than Denosumab Continuation In Postmenopausal Women
por: Hong, Namki, et al.
Publicado: (2023)

A two-cohort study on the association between the gut microbiota and bone density, microarchitecture, and strength
por: Okoro, Paul C., et al.
Publicado: (2023)

Pretreatment of daily teriparatide enhances the increase of bone mineral density in cortical bones by denosumab therapy
por: Kamimura, Mikio, et al.
Publicado: (2018)

Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone mass
por: Anastasilakis, Athanasios D., et al.
Publicado: (2019)

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
por: Miller, P. D., et al.
Publicado: (2016)

Denosumab versus zoledronic acid for patients with beta-thalassemia major-induced osteoporosis
por: Yassin, Mohamed A., et al.
Publicado: (2020)

Microarchitecture Influences Microdamage Accumulation in Human Vertebral Trabecular Bone
por: Arlot, Monique E, et al.
Publicado: (2008)

Combination Therapy With Zoledronic Acid and FES‐Row Training Mitigates Bone Loss in Paralyzed Legs: Results of a Randomized Comparative Clinical Trial
por: Morse, L R, et al.
Publicado: (2019)

Denosumab Reduces the Incidence of New Vertebral Fractures in Men With Prostate Cancer
por: Silver, David S.
Publicado: (2010)

Cardiometabolic Effects of Endocrine Treatment of Estrogen Receptor–Positive Early Breast Cancer
por: Cheung, Yee-Ming, et al.
Publicado: (2019)

Protocol of a randomised trial of teriparatide followed by zoledronic acid to reduce fracture risk in adults with osteogenesis imperfecta
por: Hald, Jannie D, et al.
Publicado: (2023)

Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab
por: Yamasaki, Mutsushi, et al.
Publicado: (2016)

Short-term efficacy and safety of zoledronate acid or denosumab in Japanese patients with postmenopausal osteoporosis
por: Nakamura, Yumejiro, et al.
Publicado: (2021)

Zoledronic Acid after Treatment with Denosumab is Associated with Bone Loss within 1 Year
por: Kadaru, Tarun, et al.
Publicado: (2021)

Denosumab/ibandronic acid/zoledronic acid: Medication-related osteonecrosis of jaw: case report
Publicado: (2021)

Effect of Denosumab on the Change of Osteoclast Precursors Compared to Zoledronate Treatment in Postmenopausal Women with Osteoporosis
por: Kong, Sung Hye, et al.
Publicado: (2022)

Combination therapy with low-dose teriparatide and zoledronate contributes to fracture healing on rat femoral fracture model
por: Tsubouchi, Yuta, et al.
Publicado: (2018)

Zoledronic acid and teriparatide have a complementary therapeutic effect on aseptic loosening in a rabbit model
por: Wang, Peng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ikq6nai576l4473ecfbuhjbajv